# A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

> **NCT06238531** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)**

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Gusacitinib

## Key facts

- **NCT ID:** NCT06238531
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-22
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-01-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug company discontinuing study.
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238531, "A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06238531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*